Martin Åmark, CEO for Xbrane Biopharma AB, becomes Head of IR for the Company





Press release

Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also been expanded with a Group Financial Controller.

For further information, please contact:
Martin Åmark
M: +46(0) 763-093 777

Susanna Helgesen
M: +46 (0) 708-278 636

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser(, +46 (0)8 409 421 20). For more information

Martin Åmark, CEO for Xbrane, becomes Head of IR

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire